Literature DB >> 27298231

Vascular stem cells-potential for clinical application.

Sadie C Slater1, Michele Carrabba1, Paolo Madeddu2.   

Abstract

INTRODUCTION: Cell therapy is a growing area of research as an alternative to pharmaceuticals or surgery for the treatment of ischaemic disease. Studies are focusing on delivering tissue-derived cells into damaged organs to promote vascular regeneration or gain of function. SOURCES OF DATA: Pubmed, clinicaltrials.gov, BHF website. AREAS OF AGREEMENT: Stem cells have the potential to become a viable treatment for many diseases, as indicated by the numerous pre-clinical studies demonstrating therapeutic benefit. AREAS OF CONTROVERSY: The mechanisms of action for transplanted stem cells are still open to debate. Proposed mechanism includes direct cell incorporation and paracrine action. Additionally, the secretome produced by transplanted cells remains largely unknown. GROWING POINTS: Initial studies focused on delivering stem cells by injection; however, current research is utilizing biomaterials to target cell delivery to specific areas. AREAS TIMELY FOR DEVELOPING RESEARCH: Whilst stem cell research in the laboratory is expanding rapidly, transition into clinical studies is hindered by the availability of equivalent clinical grade reagents.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cell therapy; myocardial infarction; scaffolds; vascular stem cells

Mesh:

Year:  2016        PMID: 27298231      PMCID: PMC5127425          DOI: 10.1093/bmb/ldw017

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  69 in total

Review 1.  Mesenchymal stem cell therapy for heart disease.

Authors:  Massimiliano Gnecchi; Patrizia Danieli; Elisabetta Cervio
Journal:  Vascul Pharmacol       Date:  2012-04-12       Impact factor: 5.773

2.  Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment.

Authors:  Chang-Hwan Yoon; Masamichi Koyanagi; Kazuma Iekushi; Florian Seeger; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Circulation       Date:  2010-04-26       Impact factor: 29.690

3.  A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction.

Authors:  Lian R Gao; Xue T Pei; Qing A Ding; Yu Chen; Ning K Zhang; Hai Y Chen; Zhi G Wang; Yun F Wang; Zhi M Zhu; Tian C Li; Hui L Liu; Zi C Tong; Yong Yang; Xue Nan; Feng Guo; Jian L Shen; Yan H Shen; Jian J Zhang; Yu X Fei; Hong T Xu; Li H Wang; Hai T Tian; Da Q Liu; Ye Yang
Journal:  Int J Cardiol       Date:  2013-05-04       Impact factor: 4.164

4.  Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial.

Authors:  Jérôme Roncalli; Frédéric Mouquet; Christophe Piot; Jean-Noel Trochu; Philippe Le Corvoisier; Yannick Neuder; Thierry Le Tourneau; Denis Agostini; Virginia Gaxotte; Catherine Sportouch; Michel Galinier; Dominique Crochet; Emmanuel Teiger; Marie-Jeanne Richard; Anne-Sophie Polge; Jean-Paul Beregi; Alain Manrique; Didier Carrie; Sophie Susen; Bernard Klein; Angelo Parini; Guillaume Lamirault; Pierre Croisille; Hélène Rouard; Philippe Bourin; Jean-Michel Nguyen; Béatrice Delasalle; Gérald Vanzetto; Eric Van Belle; Patricia Lemarchand
Journal:  Eur Heart J       Date:  2010-12-02       Impact factor: 29.983

Review 5.  Emerging models and paradigms for stem cell ageing.

Authors:  D Leanne Jones; Thomas A Rando
Journal:  Nat Cell Biol       Date:  2011-05       Impact factor: 28.824

6.  Accelerating vascularization in polycaprolactone scaffolds by endothelial progenitor cells.

Authors:  Shivani Singh; Benjamin M Wu; James C Y Dunn
Journal:  Tissue Eng Part A       Date:  2011-05-06       Impact factor: 3.845

7.  A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.

Authors:  Thomas J Povsic; Candice Junge; Adel Nada; Richard A Schatz; Robert A Harrington; Charles J Davidson; F David Fortuin; Dean J Kereiakes; Farrell O Mendelsohn; Warren Sherman; Gary L Schaer; Christopher J White; Duncan Stewart; Kenneth Story; Douglas W Losordo; Timothy D Henry
Journal:  Am Heart J       Date:  2013-04-19       Impact factor: 4.749

8.  Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair.

Authors:  Elisa Avolio; Marco Meloni; Helen L Spencer; Federica Riu; Rajesh Katare; Giuseppe Mangialardi; Atsuhiko Oikawa; Iker Rodriguez-Arabaolaza; Zexu Dang; Kathryn Mitchell; Carlotta Reni; Valeria V Alvino; Jonathan Rowlinson; Ugolini Livi; Daniela Cesselli; Gianni Angelini; Costanza Emanueli; Antonio P Beltrami; Paolo Madeddu
Journal:  Circ Res       Date:  2015-03-23       Impact factor: 17.367

9.  Percutaneous intramyocardial delivery of mesenchymal stem cells induces superior improvement in regional left ventricular function compared with bone marrow mononuclear cells in porcine myocardial infarcted heart.

Authors:  Bo Tao; Mingliang Cui; Chen Wang; Sai Ma; Feng Wu; Fu Yi; Xing Qin; Junting Liu; Haichang Wang; Zhe Wang; Xiaowei Ma; Jie Tian; Yundai Chen; Jing Wang; Feng Cao
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

10.  MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation.

Authors:  Luciana De Luca; Stefania Trino; Ilaria Laurenzana; Vittorio Simeon; Giovanni Calice; Stefania Raimondo; Marina Podestà; Michele Santodirocco; Lazzaro Di Mauro; Francesco La Rocca; Antonella Caivano; Annalisa Morano; Francesco Frassoni; Daniela Cilloni; Luigi Del Vecchio; Pellegrino Musto
Journal:  Oncotarget       Date:  2016-02-09
View more
  2 in total

Review 1.  Cell Sources for Tissue Engineering Strategies to Treat Calcific Valve Disease.

Authors:  Eva Jover; Marco Fagnano; Gianni Angelini; Paolo Madeddu
Journal:  Front Cardiovasc Med       Date:  2018-11-06

2.  Fabrication of New Hybrid Scaffolds for in vivo Perivascular Application to Treat Limb Ischemia.

Authors:  Michele Carrabba; Eva Jover; Marco Fagnano; Anita C Thomas; Elisa Avolio; Thomas Richardson; Ben Carter; Giovanni Vozzi; Adam W Perriman; Paolo Madeddu
Journal:  Front Cardiovasc Med       Date:  2020-11-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.